Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
companyunderground
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» BioMarin sells its PhIII cancer drug to Medivation for $570M
BioMarin sells its PhIII cancer drug to Medivation for $570M
BioMarin sells its PhIII cancer drug to Medivation for $570M
Submitted by
admin
on August 24, 2015 - 11:22am
Source:
Fierce Biotech
News Tags:
Biomarin
Medivation
talazoparib
breast cancer
BRCA1
BRCA2
Headline:
BioMarin sells its PhIII cancer drug to Medivation for $570M
Do Not Allow Advertisers to Use My Personal information
